Farther Finance Advisors’s Pacira BioSciences PCRX Stock Holding History

Farther Finance Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.21K	Sell	245 -8,150	-97%	-$193K	﹤0.01%	4679
2026 Q1	$191K	Sell	8,395 -922	-10%	-$20.5K	﹤0.01%	2049
2025 Q4	$241K	Buy	9,317 +1,145	+14%	+$27.2K	﹤0.01%	1798
2025 Q3	$211K	Buy	8,172 +12	+0.1%	+$295	﹤0.01%	1578
2025 Q2	$195K	Buy	8,160 +7,651	+1,503%	+$193K	﹤0.01%	1403
2025 Q1	$12.3K	Buy	+509	New	+$12.2K	﹤0.01%	2642
2024 Q4	–	Sell	-8	Closed	-$120	–	4107
2024 Q3	$120	Sell	8 -22	-73%	-$376	﹤0.01%	3747
2024 Q2	$854	Buy	30 +26	+650%	+$740	﹤0.01%	3123
2024 Q1	$117	Sell	4 -38	-90%	-$1.17K	﹤0.01%	3355
2023 Q4	$1.42K	Buy	42 +37	+740%	+$1.08K	﹤0.01%	2579
2023 Q3	$153	Buy	+5	New	+$180	﹤0.01%	2504
2023 Q2	–	Sell	-15	Closed	-$612	–	2545
2023 Q1	$612	Buy	+15	New	+$597	﹤0.01%	1955

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Farther Finance Advisors's PCRX Position: Q2 2026 in Review

Farther Finance Advisors reduced its Pacira BioSciences (PCRX) stake by 97% in Q2 2026, selling an estimated $193K and leaving 245 shares worth $6.21K. The position accounts for ﹤0.01% of the portfolio, ranked #4679.

Farther Finance Advisors first reported a position in PCRX in Q1 2023 and has held it in 12 quarters since. The position peaked at $241K in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Farther Finance Advisors held 245 shares of Pacira BioSciences worth $6.21K as of Q2 2026.
Farther Finance Advisors sold 8,150 Pacira BioSciences shares in Q2 2026, an estimated $193K.
Pacira BioSciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4679 holding.
Farther Finance Advisors first reported a position in Pacira BioSciences in Q1 2023 and has held it in 12 quarters since.
Farther Finance Advisors's Pacira BioSciences position peaked at $241K in Q4 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.